Amber Welle

Bachelor of Medicine and Bachelor of Science,  The Johns Hopkins Hospital 

Location: United States

Consulting Services

Career Advice and Mentoring Hospital-Pharmacy-Insurance

Areas Of Interest

Mi-2 Nucleosome Remodeling and Deacetylase Complex Acrichine Hydrogen Deuterium Exchange-Mass Spectrometry Promoters, rRNA Chromatography, Gas Liquid Mass Spectrometry Pyrophosphokinase, GTP Phosphotyrosine-Independent Ligand For The Lck SH2 Domain Of 62 Kda Suit, Gravity Permanent Vegetative State Healings, Spiritual Diseases, Pleural Infections, Paragonimus Loss of Function Mutation MEF2C Protein Pityrosporum orbiculare Porcine Encephalomyelitis, Enzootic Trypanosomicidal Agents Ba34,276 Activator, C3 Disease, Parasitic Skin Myoporums

Professional Narrative

Dr. Amber Welle was born in DuBois, Pennsylvania and is a graduate of Villanova University. He obtained his medical degree at Thomas Jefferson University in Philadelphia. His residency was at Thomas Jefferson and its affiliated Wills Eye Hospital, and he completed his training with fellowships at the University of Connecticut incataract andcorneal surgery.

Dr. Welle has thirty years’ experience in ophthalmic surgery,withspecialinterestin cataract surgery,corneal transplantation,andlaserrefractiveprocedures.Heisa founding member of Precision LASIK Group, Chief of Ophthalmology at The Hospital ofCentral Connecticut,andco-medical director of the Connecticut eye bank.


Employment

Executive Director, Harvard Med 1994
Senior Director, Harvard Med 1988

Education

Doctor of medicine, Weill Medical College 1998
Doctor of osteopathic medicine, Perelman School of Medicine 1990

Referees


Publications

Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, Anderson DG, Langer R, Blankschtein D. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017 Mar 8;17(3):1326-1335. doi: 10.1021/acs.nanolett.6b03329. Epub 2016 Dec 5. PMID: 28273716; PMCID: PMC5523404.

Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 2016;7(5):319-34. doi: 10.4155/tde-2016-0006. Erratum in: Ther Deliv. 2016 Jun;7(6):411. PMID: 27075952; PMCID: PMC5439223.

Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 2016;7(5):319-34. doi: 10.4155/tde-2016-0006. Erratum in: Ther Deliv. 2016 Jun;7(6):411. PMID: 27075952; PMCID: PMC5439223.

Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 2016;7(5):319-34. doi: 10.4155/tde-2016-0006. Erratum in: Ther Deliv. 2016 Jun;7(6):411. PMID: 27075952; PMCID: PMC5439223.


Grants,Awards and Certifications

Grants :

No Grants Mentioned !!

Awards & Prizes :


Languages

Language Proficiency :

Translation Services :